Insmed (STU:IM8N) Other Current Receivables: €0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:IM8N Insmed Inc STU:IM8N
71 GF Score
Price €85.69
GF Value €161.73
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Insmed Other Current Receivables?

Insmed STU:IM8N +0.08% 71 Other Current Receivables is €0.0 Mil as of Mar. 2026. GuruFocus rates STU:IM8N with a GF Score™ of 71/100 and a GF Value™ of €161.73 (Possible Value Trap). The stock has 4 warning signs investors should review.

Insmed's Other Current Receivables for the quarter that ended in Mar. 2026 was €0.0 Mil.

Insmed Other Current Receivables Related Terms

Insmed Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Insmed's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insmed Other Current Receivables Chart

Insmed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Insmed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:IM8N
71GF Score
Insmed Inc STU:IM8N
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Insmed Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of €0.0 Mil mean?
Insmed (STU:IM8N) has a Other Current Receivables of €0.0 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Insmed and its competitors.
Is Insmed's Other Current Receivables too high?
Insmed's current Other Current Receivables is €0.0 Mil. Overall, Insmed has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Insmed's Other Current Receivables compare to INCY and BNTX?
Insmed's Other Current Receivables of €0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Insmed and its competitors. Insmed's current Other Current Receivables is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insmed stock overvalued right now?
Based on GuruFocus' analysis, Insmed (STU:IM8N) is currently considered Possible Value Trap. The stock's GF Value™ is €161.73, compared to a current price of €85.69 — trading 47% below its estimated fair value. The current Other Current Receivables is €0.0 Mil. Insmed's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Insmed (STU:IM8N), the current Other Current Receivables is €0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insmed (STU:IM8N) Overvalued in 2026?

Based on GuruFocus' analysis, Insmed stock appears to be undervalued. The current stock price of €85.69 is trading 47% below its estimated GF Value™ of €161.73. GuruFocus considers Insmed to be Possible Value Trap.

Key valuation signals for STU:IM8N:

  • Other Current Receivables: €0.0 Mil
  • GF Value™: €161.73 vs. price of €85.69 (47% below fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the STU:IM8N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Insmed Business Description

Address 700 US Highway 202/206, Bridgewater, NJ, USA, 08807
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
71GF Score

Get the complete analysis for STU:IM8N

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€85.69
Price
€161.73
GF Value